Association Between the Atherogenic Index of Plasma and the Occurrence of Slow Flow/No-Reflow in Patients With Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention.

Authors

Qinyu Sun, Yifan Deng, Weiyi Zhou, Zhoujun Huang, Shenghu He, Jing Zhang, Wei Zhou

Published in

Cardiology research and practice. Volume 2026. Pages 4736031. Epub Sep 12, 2026.

Abstract

Percutaneous coronary intervention (PCI) is the primary reperfusion strategy for acute myocardial infarction (AMI); however, some patients develop slow flow/no-reflow (SF/NR) after the procedure, which adversely affects prognosis. Atherogenic index of plasma (AIP) is a reliable biomarker of cardiovascular risk, yet its predictive value for SF/NR following emergency PCI in AMI patients remains unclear.
This study aimed to investigate the association between AIP and the occurrence of SF/NR in AMI patients undergoing emergency PCI.
A retrospective analysis was conducted on 964 patients initially diagnosed with AMI who underwent PCI. The participants were categorized into SF/NR (n = 251) and normal flow (n = 713) groups on the basis of TIMI flow grade. Statistical analyses including LASSO regression, multivariate logistic regression, ROC curve analysis, RCS regression, subgroup analysis, and the development of a nomogram model were performed.
AIP was identified as an independent risk factor for postoperative SF/NR (OR = 3.184, p < 0.05). The AUC for AIP in the prediction of SF/NR was 0.737. Higher AIP quartiles were associated with increased risk, and a nonlinear relationship was observed. The constructed nomogram model demonstrated good predictive performance (AUC = 0.745), satisfactory calibration in internal validation, and favorable clinical utility. Subgroup analysis confirmed the consistent predictive ability of AIP across different strata.
AIP may be associated with the risk of SF/NR after emergency PCI in AMI patients. Combined with white blood cell count and triglyceride levels, AIP could potentially assist in early identification of high-risk individuals, which warrants further validation in prospective studies. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2500108501.

PMID:
42732387
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.